Streptococcus constellatus (S. constellatus)

Streptococcus constellatus is a Gram-positive, catalase-negative bacterium that belongs to the Streptococcus anginosus group (SAG), historically referred to as the Streptococcus milleri group (Whiley et al., 1991, Journal of Clinical Microbiology). It is a common commensal inhabitant of the human oral cavity, gastrointestinal tract, and urogenital tract, but it is recognized as a significant opportunistic pathogen (Reissmann et al., 2010, Laryngoscope). S. constellatus is particularly distinguished from other streptococci by its strong association with the formation of purulent abscesses in various anatomical sites, including the brain, liver, and lungs (Giuliano et al., 2012, European Review for Medical and Pharmacological Sciences). In clinical infections, it often appears as part of a polymicrobial flora, frequently co-isolated with obligate anaerobes, which may enhance its virulence and tissue-destructive capabilities (Claridge et al., 2001, Clinical Microbiology Reviews). Therapeutic management typically involves the use of beta-lactam antibiotics, such as penicillin or ceftriaxone, although the presence of abscesses often necessitates surgical drainage alongside prolonged antimicrobial therapy (Kobayashi et al., 2017, Journal of Infection and Chemotherapy). While generally considered susceptible to many antibiotics, its role in deep-seated, life-threatening infections makes it a critical focus in clinical microbiology and infectious disease management.

Other names

Streptococcus milleri groupStreptococcus anginosus groupSAGStreptococcus constellatus subsp. constellatusStreptococcus constellatus subsp. pharyngis

Antibiotics targeting Streptococcus constellatus primarily function by inhibiting bacterial cell wall peptidoglycan synthesis (e.g., beta-lactams and glycopeptides) or by interfering with bacterial protein synthesis at the ribosomal level (e.g., lincosamides and macrolides) (Claridge et al., 2001, Clinical Microbiology Reviews).